CliffBio
biologic

Avlayah

tividenofusp alfa-eknm

Loss of exclusivityMarch 2038projected — 12-year biologic exclusivity estimate
CompanyDenali Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameAvlayah
Active ingredienttividenofusp alfa-eknm
Strength150MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2026
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Avlayah patent cliff — loss of exclusivity March 2038 | CliffBio